Heparin-induced thrombocytopenia cost-effectiveness of therapy

Heparin-induced thrombocytopenia
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Heparin-induced thrombocytopenia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Heparin-induced thrombocytopenia cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Heparin-induced thrombocytopenia cost-effectiveness of therapy
CDC on Heparin-induced thrombocytopenia cost-effectiveness of therapy
Heparin-induced thrombocytopenia cost-effectiveness of therapy in the news
Blogs on Heparin-induced thrombocytopenia cost-effectiveness of therapy
Directions to Hospitals Treating Heparin-induced thrombocytopenia
Risk calculators and risk factors for Heparin-induced thrombocytopenia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]

Cost-Effectiveness of Therapy

There has been one cost-effective analysis of anticoagulants for HIT. The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors. Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin.

	Argatroban	Bivalirudin	Fondaparinux
Cost of administration	$411.43	$411.43	$25.40
Average wholesale price	$1194.65 (1 vial of 250mg)	$753.07 (1 vial of 250mg)	$220.34 (1 syringe of 7.5mg)
Total cost for 9 days of therapy	$1326	$1562	$164

As novel anticoagulants become FDA-approved and arrive to the market, cost-effective analysis will need to be considered. Note that newer generation medications typically have higher costs than traditional medications.